JPMorgan Chase & Co. decreased its position in Natus Medical Incorporated (NASDAQ:BABY) by 58.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,868 shares of the medical equipment provider’s stock after selling 125,265 shares during the period. JPMorgan Chase & Co.’s holdings in Natus Medical were worth $3,528,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in Natus Medical during the fourth quarter worth $1,184,000. Comerica Bank boosted its position in Natus Medical by 5.6% in the fourth quarter. Comerica Bank now owns 35,353 shares of the medical equipment provider’s stock worth $1,370,000 after buying an additional 1,865 shares in the last quarter. State Street Corp boosted its position in Natus Medical by 5.3% in the fourth quarter. State Street Corp now owns 747,165 shares of the medical equipment provider’s stock worth $25,998,000 after buying an additional 37,378 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Natus Medical by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,363,441 shares of the medical equipment provider’s stock worth $47,448,000 after buying an additional 29,472 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Natus Medical by 247.0% in the fourth quarter. Renaissance Technologies LLC now owns 45,800 shares of the medical equipment provider’s stock worth $1,594,000 after buying an additional 32,600 shares in the last quarter. 93.66% of the stock is currently owned by institutional investors and hedge funds.

Shares of Natus Medical Incorporated (BABY) traded up 0.14% during midday trading on Friday, reaching $34.90. 286,892 shares of the company’s stock traded hands. The company has a 50-day moving average of $36.71 and a 200-day moving average of $36.90. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 61.34 and a beta of 0.93. Natus Medical Incorporated has a one year low of $33.15 and a one year high of $44.39.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. During the same period in the previous year, the business earned $0.39 earnings per share. The company’s revenue for the quarter was up 27.3% compared to the same quarter last year. Equities research analysts anticipate that Natus Medical Incorporated will post $1.70 EPS for the current year.

TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Sells 125,265 Shares of Natus Medical Incorporated (NASDAQ:BABY)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/04/jpmorgan-chase-co-has-3-53-million-position-in-natus-medical-incorporated-nasdaqbaby-updated-updated-updated.html.

BABY has been the subject of a number of research reports. Benchmark Co. reissued a “buy” rating and issued a $48.00 price target (down previously from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. TheStreet cut shares of Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $45.00.

In other Natus Medical news, Director Doris Engibous sold 5,000 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total transaction of $163,400.00. Following the sale, the director now directly owns 22,650 shares in the company, valued at $740,202. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider James B. Hawkins bought 6,000 shares of the firm’s stock in a transaction on Wednesday, May 31st. The shares were purchased at an average price of $33.81 per share, for a total transaction of $202,860.00. The disclosure for this purchase can be found here. 5.50% of the stock is owned by insiders.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.